According to a report by Reuters on Wednesday, New Jersey-based Amicus Therapeutics Inc. (NASDAQ:FOLD) announced that in a 24-month trial, its new drug migalastat was effective at reducing abnormal fat accumulation in kidney cells compared with placebo. The drug is being considered alone and in combination therapy for treating Fabry disease, a congenital disorder that can be debilitating and even fatal. Amicus Therapeutics, Inc. (NASDAQ:FOLD) stock performance was 20.65% in last session and finished the day at $2.22. Traded volume was 5.42million shares in the last session and the average volume of the stock remained 319.04K shares. The beta of the stock remained 1.06. Amicus Therapeutics, Inc. (NASDAQ:FOLD) insider ownership is 2.90%.

Synthetic Biologics, Inc. (NYSE:SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, reported today that the University of California, Los Angeles (UCLA) School of Medicine announced preliminary, positive topline data from the Phase II clinical trial evaluating Trimesta™ (oral estriol), the Company’s oral, once-daily treatment for relapsing-remitting multiple sclerosis (RRMS) in women. Synthetic Biologics Inc (NYSEMKT:SYN) dropped -27.84 percent to $2.10 Tuesday on volume of 5.13million shares. The intra-day range of the stock was $2.00 to $3.03. Synthetic Biologics Inc (NYSEMKT:SYN) has a market capitalization of $12.38million.

TheStreet Quant Ratings rates IsoRay Inc. (NYSEMKT:ISR) as a sell. The company’s weaknesses can be seen in multiple areas, such as its disappointing return on equity, weak operating cash flow and poor profit margins. IsoRay, Inc. (NYSEMKT:ISR)’s stock on Apr 29, 2014 reported a decrease of -8.82% to the closing price of $1.86. Its fifty two weeks range is $0.44 -$3.77. The total market capitalization recorded $100.43million. The overall volume in the last trading session was 3.47million shares. In its share capital, ISR has 53.99million outstanding shares.

Ultra Clean Holdings Inc (NASDAQ:UCTT) announced its earnings results on Monday. The company reported $0.27 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.30 by $0.03. On Tuesday, shares of Ultra Clean Holdings Inc (NASDAQ:UCTT) dropped -26.08% to close the day at $8.73. Company return on investment (ROI) is 6.00% and its monthly performance is recorded as -29.99%. Ultra Clean Holdings Inc (NASDAQ:UCTT) quarterly revenue growth is -25.64%.